Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells

Andreas Kupz1, Saparna Pai1, Paul R. Giacomin1, Jennifer A. Whan2, Robert A. Walker1, Pierre-Mehdi Hammoudi3, Nicholas C. Smith4,5,7 & Catherine M. Miller2,6,7

Toxoplasma encephalitis is an AIDS-defining condition. The decline of IFN-γ-producing CD4+ T cells in AIDS is a major contributing factor in reactivation of quiescent Toxoplasma gondii to an actively replicating stage of infection. Hence, it is important to characterize CD4-independent mechanisms that constrain acute T. gondii infection. We investigated the in vivo regulation of IFN-γ production by CD8+ T cells, DN T cells and NK cells in response to acute T. gondii infection. Our data show that processing of IFN-γ by these non-CD4 cells is dependent on both IL-12 and IL-18 and the secretion of bioactive IL-18 in response to T. gondii requires the sensing of viable parasites by multiple redundant inflammasome sensors in multiple hematopoietic cell types. Importantly, our results show that expansion of CD8+ T cells, DN T cells and NK cell by S4B6 IL-2 complex pre-treatment increases survival rates of mice infected with T. gondii and this is dependent on IL-12, IL-18 and IFN-γ. Increased survival is accompanied by reduced pathology but is independent of expansion of Treg cells or parasite burden. This provides evidence for a protective role of IL2C-mediated expansion of non-CD4 cells and may represent a promising lead to adjunct therapy for acute toxoplasmosis.

Toxoplasma gondii (T. gondii) is an obligate intracellular parasite of the phylum Apicomplexa1. It is estimated that one-third of the world’s population is infected with T. gondii. In most individuals, infection is asymptomatic and leads to chronic, life-long persistence of T. gondii-containing cysts, primarily in brain and muscle tissue5. Active disease, also known as toxoplasmosis, usually occurs after reactivation of encysted parasites, and is often associated with immunosuppression. If untreated, toxoplasmosis may be fatal. Additionally, serious eye disease has been reported as a result of infection with T. gondii and, if a primary infection occurs during pregnancy, abortion, stillbirth and fetal abnormalities can occur6,7. Whereas an acute infection is generally mediated by the fast-replicating tachyzoite stage of the parasite, the persistent tissue cysts, characteristic of a chronic infection, contain slow-replicating bradyzoites. Currently, treatment of toxoplasmosis is limited to the acute disease and requires prolonged exposure to anti-toxoplasmosis drugs for the duration of the immunosuppression6,8.

1Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia. 2Advanced Analytical Centre, James Cook University, Cairns, QLD 4878, Australia. 3Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland. 4School of Science and Health, Western Sydney University, Parramatta South Campus, Sydney, NSW 2116, Australia. 5School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia. 6Discipline of Biomedicine, College of Public Health, Medical and Veterinary Science, James Cook University, Cairns, QLD 4878, Australia. 7These authors jointly supervised this work: Nicholas C. Smith and Catherine M. Miller. *email: andreas.kupz@jcu.edu.au
Containment of chronic *T. gondii* infection requires functional T-cell responses, in particular interferon gamma (IFN-γ)-producing CD4^+^ T cells. In the absence of CD4^+^ T cells, IFN-γ, its receptor or downstream effector molecules, such as inducible nitric oxide synthase (iNOS), susceptibility and disease are severely exacerbated. Accordingly, co-infection with human immunodeficiency virus (HIV), which impairs CD4^+^ T cells during its reproduction, is one of the major reactivation factors. In fact, toxoplastic encephalitis accompanied by low numbers of CD4^+^ T cells is considered to be an AIDS-defining condition in HIV^+^ individuals.

In addition to antigen-specific CD4^+^ T cells, innate immune cells, such as NK cells and neutrophils also contribute significantly to the production of host-protective IFN-γ. In particular, the recognition of *T. gondii*-derived profilin via Toll-like receptor (TLR)-11, which drives myeloid differentiation primary response protein 88 (MyD88)-dependent IL-12 secretion by dendritic cells, is considered a crucial upstream pathway of protective IFN-γ secretion. MyD88 or IL-12 knock-out mice are also susceptible to *T. gondii* infection. Furthermore, elegant studies by Hunter and colleagues showed that T cell-intrinsic ablation of MyD88 also impacts severely on the control of the parasite. These findings indicate that, in addition to IL-12, cytokine-driven IFN-γ secretion in response to *T. gondii* also relies on IL-18, an IL-1 family cytokine originally known as IFN-γ-inducing factor, which requires cell-intrinsic MyD88 signaling. IL-18 is particularly important for the rapid secretion of IFN-γ by cells of the immune system, in particular NK cells, CD8^+^ memory T cells and double negative (DN) γδ T cells.

Proteolytic cleavage of IL-18 from biologically inactive pro-IL-18 requires caspase-1 and the activation of cytosolic inflammasome sensors. Deficiencies in caspase-1, IL-18 and the inflammasome sensors NLRP1 and NLRP3 are associated with compromised immunity to *T. gondii* and several intracellular bacterial pathogens. Hence, the positive impact of targeting IL-18-mediated IFN-γ production on protective immunity has been demonstrated in models of *Listeria monocytogenes*, *Mycobacterium tuberculosis* and *Salmonella enterica* infection.

Given that control of acute toxoplasmosis depends on a delicate balance between limiting immunopathology and maintaining parasite killing, in the present study, we interrogated the regulation of IL-18-driven IFN-γ production in vivo. We discovered that bioactive IL-18 is dependent on the sensing of viable parasites by multiple redundant inflammasome sensors in multiple hematopoietic cell types, leading to the hypothesis that enhancement of this innate response could be harnessed to prevent disease resulting from infection with *T. gondii*. We therefore investigated if treatment with S4B6-containing IL2C, an IL2 complex that can boost NK and CD8^+^ T cell numbers, could prevent acute lethal toxoplasmosis.

**Results**

**Toxoplasma-driven IFN-γ secretion by non-CD4 immune cells following oral infection with brain cysts or intravenous (i.v.) infection with tachyzoites.** Given that control of acute toxoplasmosis critically depends on IFN-γ and non-CD4 immune cell types, such as CD8^+^ T cells, DN T cells and NK cells, are prime IFN-γ producers, we wanted to delineate the mechanistic requirements of IFN-γ production by these cell types in response to *T. gondii*. We furthermore wanted to explore whether responses were similar after oral infection (a common natural route of infection, i.v. infection with tachyzoites (modelling blood transfusion), a rare but significant—for the individual—route of infection and the often used purely experimental i.p. route of infection with tachyzoites.

We first inoculated naïve B6 mice with 10, 40 or 100 *T. gondii* ME49 cysts and assessed IFN-γ production by viable splenic CD3^+^CD4^−^CD8^−^ (DN) T cells and CD3^+^NKp46^+^ cells 1 day and 5 days after inoculation. Whereas no IFN-γ production was observed 1 day after inoculation, a significant increase in IFN-γ-secreting cells was detected at 5 days after inoculation in spleen (Fig. 1a,b), mesenteric lymph nodes (MLN) (Fig. 1e,f) and Peyer's Patches PP (Fig. 1a,b). Up to 10% of CD8^+^ T cells and DN T Cells and up to 50% of all NK cells stained IFN-γ^+^, particularly following inoculation with 40 and 100 cysts.

We also investigated if rapid IFN-γ production could be induced by inoculation with tachyzoites via the i.v. and i.p. routes using a short-term in vivo exposure model in which naïve B6 mice were exposed to *T. gondii* tachyzoites for a maximum of 72 h. When mice were injected i.v. or i.p. with 10^7^ tachyzoites, no significant IFN-γ production could be seen in either spleen, MLN or PP within 72 h (Fig. 1e). However, i.v. or i.p. inoculation with 10^7^ tachyzoites led to secretion of IFN-γ by CD3^+^CD8^+^, CD3^+^CD4^−^CD8^−^ (DN) T cells and CD3^+^NKp46^+^ cells in spleen, MLN and PP as early as 2–24 h after inoculation (Fig. 1c,d,g,h; Fig. 1c,d,m). However, results seen 5 days after a cyst inoculation (Fig. 1b,f). Importantly, at 24 h after tachyzoite inoculation, levels of other acute inflammatory mediators, such as IL-6, TNFa and IL-10, were almost indistinguishable from naïve mice (Fig. 11–k), indicating that these cytokines were not impacting on protective IFN-γ responses 24 h after i.v. infection.

These results show that i.v. i.p. tachyzoite infections and oral brain cyst infections induce almost identical acute immune responses. Given that it is difficult to quantify the number of bradyzoites within brain cysts used for oral infection and, moreover, dissemination patterns following oral infection are erratic in individual mice, we subsequently focused on IFN-γ secretion 24 h after i.v. injection of tachyzoites as our primary readout for further dissection of the underlying mechanistic requirements.

**Rapid IFN-γ secretion in response to *T. gondii* requires IL-12 and IL-18.** Whereas the role of IL-12 in IFN-γ secretion is well established for *T. gondii* rapid production of IFN-γ in response to other intracellular pathogens, such as *S. enterica*, *L. monocytogenes* and *M. tuberculosis* has also been linked to the upstream effects of IL-18. To interrogate whether or not, and how early, IFN-γ secretion in response to *T. gondii* also requires IL-18, we exposed naïve B6 mice to *T. gondii* ME49 tachyzoites and treated the animals with neutralizing monoclonal antibodies (mAb) to IL-12, IL-18 or IL-12 and IL-18 immediately after inoculation. We focused...
on NK cells for these and subsequent experiments, since this was the cell type for which the highest proportion of cells stained positive for IFN-γ following inoculation with *T. gondii* (see Fig. 1). At 24 h after exposure, we assessed IFN-γ secretion by NK cells in the spleen ex vivo. Neutralization of IL-12 and IL-18 significantly reduced IFN-γ production, with IL-12 contributing approximately 50% and IL-18 approximately 30–40% of...
the response (Fig. 2a). Consistent with this, where IL-12 levels in the serum of infected mice peaked at approximately 2 h after inoculation, the levels of IL-18 mirrored those of IFN-γ for up to 72 h (Fig. 2b). The significant reduction of rapid IFN-γ production in IL18−/− mice, and the almost complete absence of rapid IFN-γ production in anti-IL-12-treated IL18−/− mice, further confirmed a direct correlation between IL-12, IL-18 and IFN-γ secretion (Fig. 3c,d). Furthermore, treatment with anti-IL-12 and anti-IL-18 also reduced concentrations of IFN-γ, IL-12 and IL-18 in the serum of infected mice in an additive manner (Fig. 2d–f). These results suggest a hierarchical relationship in which a primary IL-12-driven IFN-γ response is followed by an IL-18-dominant IFN-γ response. We concluded that innate IFN-γ secretion in response to T. gondii is driven by the secretion of IL-12 and IL-18.

**IL-18-driven IFN-γ secretion to T. gondii depends on multiple redundant inflamasomes.** Given that the molecular mechanisms that lead to T. gondii-mediated IL-12 secretion are well characterized, we focused our attention on the host signaling pathways required for IL-18-driven IFN-γ production, using a panel of genetically modified mouse strains. Secretion of bioactive IL-18 depends on the inflammasome, a process that can be enhanced and controlled via TRIF-dependent caspase-11 activation. A significantly increased percentage of IFN-γ NK cells was seen in Caspase1/11−/− double KO mice, Nlrp1−/−, Nlrp3−/− and heterozygous Nlrp1+/−Nlrp3+/−, Nlrp1−/−Nlrp3−/− and Nlrp1−/−Nlrp3−/− mice infected with T. gondii versus uninfected mice, and this response could be almost completely prevented by additional anti-IL-12 treatment (Fig. 3a, Table S1). Caspase1/11−/− double KO mice, Nlrp1−/− mice and Nlrp3−/− mice produced statistically significantly less IFN-γ following injection with T. gondii ME49 tachyzoites compared with B6 mice but, counter-intuitively, heterozygous Nlrp1+/−Nlrp3+/−, Nlrp1−/−Nlrp3−/− and Nlrp1−/−Nlrp3−/− mice did not; this may indicate a statistical rather than biological significance to these particular data, the key observation being that all mice are capable of generating significant numbers of IFN-γ cells.

As expected, Caspase1/11−/− mice did not secrete significant levels of IL-18 following T. gondii inoculation (Fig. 3b), indicating that the remaining IFN-γ response in Caspase1/11−/− mice is driven by IL-12. Surprisingly, when we tested mice deficient in the upstream NLR family pyrin domain-containing proteins 1 and 3 (NLRP1 and NLRP3), NLR molecules that had been implicated previously in recognition of T. gondii20 both knockout strainssecreted indistinguishable amounts of IL-18 compared with B6 mice (Fig. 3b; Table S2). This data suggested a redundant role for NLRP1 and NLRP3. However, even double knockout and heterozygous Nlrp1−/−Nlrp3−/−, Nlrp1−/−Nlrp3−/− and Nlrp1−/−Nlrp3−/− mice secreted high levels of IL-18 after exposure to T. gondii ME49 tachyzoites (Fig. 3b; Table S2), suggesting that additional PRR molecules must be involved in sensing of T. gondii invasion in vivo. Taken together these results indicate that rapid IFN-γ secretion in vivo in response to T. gondii depends on the inflammasome → caspase-1 → IL-18 axis, and that T. gondii likely activates at least three different inflamasomes in vivo.

**Toxoplasma gondii activates inflamasomes in multiple cell types.** To further investigate the role of cytosolic PRRs in sensing T. gondii invasion, and to potentially target inflammasome activation for preventive or therapeutic intervention strategies, we next tried to identify the T. gondii-sensing cell type in vivo. To do this, we made use of a red fluorescent protein (RFP) tagged T. gondii ME49 (T. gondii ME49-RFP) strain to track parasite uptake by different immune cell subsets in the spleen. Twenty-four hours after tachyzoite injection, T. gondii ME49-RFP also induced rapid IFN-γ secretion by splenic CD3+CD4+, CD3+CD8+, CD3+CD4−CD8− (DN) T cells and CD3+CD4−CD8− cells (Fig. 4a) and high levels of serum IL-18 (Fig. 4b), similar to wild-type T. gondii ME49 (see Figs. 1 and 2). Approximately 0.5% of all splenocytes contained T. gondii ME49-RFP in vivo 24 h after inoculation (Fig. 4c). Sorted RFP+ cells secreted significantly more IL-18 ex vivo compared to RFP− cells (Fig. 4d), and further surface phenotyping revealed that T. gondii ME49-RFP was primarily contained in monocytes, neutrophils and CD8α+ dendritic cells (Fig. 4e,f). Splenic MHC-II+CD11c+ DCs, CD11b+Ly6G− neutrophils and CD11b+Ly6C+ monocytes each comprised approximately 20–30% of all RFP-containing cells after i.v. tachyzoite injection. Only very few T cells, B cells and macrophages appeared to harbor parasites (Fig. 4e,f). To investigate if cell types that contained T. gondii ME49-RFP parasites also activated inflamasomes, we performed intracellular staining for the inflammasome adaptor molecule apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC), and measured the activation of caspase-1 with a fluorescent inhibitor that only binds to activated caspase-1 (FLICA FAM-YVAD-FMK)20. Consistent with the uptake of T. gondii ME49-RFP by different cell types, T. gondii ME49-RFP parasite-harboring neutrophils, monocytes and DCs all expressed higher levels of ASC and FAM-YVAD compared with RFP− cells and FMO controls (Fig. 4g). Collectively, these results indicate that T. gondii infection activates multiple redundant inflamasomes in multiple different hematopoietic cell-types in vivo.

**IL-18-driven IFN-γ secretion to T. gondii depends on viable parasites but is independent of secreted GRA proteins.** Next, we assessed if rapid IFN-γ secretion in response to T. gondii required viable parasites or could be induced by soluble factors. To this end, naive B6 mice were injected with either live, heat-killed or sonicated T. gondii ME49 tachyzoites. Inoculation with live parasites induced significantly increased IFN-γ secretion by NK cells and increased serum IL-18 levels compared to heat-killed or sonicated parasites (Fig. 5a,b). To exclude the possibility that heat inactivation and sonication destroyed soluble factors that could potentially drive this response, we also injected naive B6 mice with HFF cell debris, which had been re-suspended in the T. gondii ME49 culture supernatant. This treatment also failed to induce IFN-γ and IL-18 secretion (Fig. 5a,b). These results indicated that viable parasites are required to initiate an IFN-γ response, suggesting that
Figure 2. Rapid IFN-γ production in response to *T. gondii* requires IL-12 and IL-18. (a) Percent of IFN-γ+ cells amongst total viable CD3–NKp46+ cells in the spleen 24 h after B6 mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/or IL-12 immediately after injection of *T. gondii*. (b) Serum concentrations of IL-18, IL-12p70 and IFN-γ at various time points after B6 mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. (c) Percent of IFN-γ+ cells amongst total viable CD3–NKp46+ cells in the spleen 24 h after B6 or Il18−/− mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-12 immediately after injection of *T. gondii*. (d) Serum concentrations of IL-18 24 h after B6 or Il18−/− mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-12 immediately after injection of *T. gondii*. (e) Serum concentrations of IFN-γ 24 h after B6 or Il18−/− mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/or IL-12 immediately after injection of *T. gondii*. (f) Serum concentrations of IL-12 24 h after B6 or Il18−/− mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/or IL-12 immediately after injection of *T. gondii*. Results are presented as individual data points (a,c,d,e,f) or as means ± SEM (b) of 4–15 mice per group from at least two pooled independent experiments. Statistical analyses: One-way ANOVA followed by Dunnett’s multiple comparison test. Significant differences are indicated by asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

*T. gondii* virulence factors may play a critical role. Evidence from studies that have investigated the mechanistic framework of how intracellular bacterial pathogens activate inflammasomes in vivo, suggests that secreted effector molecules and/or distinct structural proteins are critically required. Apicomplexan parasites also secrete
IL2C treatment expands IL-18-responsive IFN-γ-secreting cell subsets. Collectively, the results presented so far raise the prospect that, if the ability of non-CD4 cells to invoke inflammasome-dependent, IL-18-driven production of IFN-γ can be enhanced, it may be possible to control acute toxoplasmosis in AIDS. Hence, we investigated if targeted expansion of non-CD4 cells with IL2C treatment can achieve this. First, naïve mice were treated i.p. with IL2C complex on four consecutive days (Fig. 6a) and, 24 h after the last IL2C injection, immune cell expansion was assessed by flow cytometry relative to untreated animals. As reported previously, IL2C treatment led to a significant expansion of memory CD8+ T cells, NK cells and DN T cells in spleen and MLN (Fig. 6b,c) though increases observed in the PP were not statistically significant (Fig. 6d). Next we assessed if IL2C-expanded and non-expanded CD8+ T cells, DN T cells and NK cells responded similarly to T. gondii infection. IL2C-treated and untreated mice were infected with 10^7 ME49 tachyzoites for 24 h (Fig. 6a). The percentage of CD8+ T cells, DN T cells and NK cells producing IFN-γ was almost indistinguishable between IL2C-treated and untreated mice (Fig. 6e). The number of IFN-γ+ NK cells, IFN-γ+ CD8+ T cells and IFN-γ+ DN T cells increased 3–30 fold following IL2C treatment (Fig. 6f). Similarly, IL2C pretreatment significantly increased systemic IFN-γ levels in the serum after i.v. infection (Fig. 6g) but, as expected, did not lead to a significant change in the levels of serum IL-18 (Fig. 6h). We also assessed the expression of IL18R and IL12R on the surface of IFN-γ+ and IFN-γ- cells. IFN-γ+ NK cells (data for CD8+ T cells and DN T cells not shown) expressed significantly higher levels of IL18R and IL12R compared to IFN-γ- NK cells (Fig. 6i). Taken together, these results show that IL2Cexpanded cells respond similarly to non-expanded cells and that the effect of IL2C
Figure 4. *T. gondii* activates inflammasomes in multiple cell types. (a) Percent of IFN-γ+ cells amongst total viable splenic CD3+CD4+, CD3+CD8+, CD3+CD4−CD8− (DN) T cells and CD3−NKp46+ cells in naïve mice 24 h after i.v. injection of 10⁷ *T. gondii* ME49-RFP tachyzoites. (b) Serum IL-18 levels in naïve mice 24 h after i.v. injection of 10⁷ *T. gondii* ME49-RFP tachyzoites. (c) Representative FACS plots showing total viable splenic RFP+ cells 24 h after i.v. injection of 10⁷ *T. gondii* ME49-RFP tachyzoites. (d) IL-18 levels in supernatant of sorted RFP+ and RFP− cells after incubation at 37 °C for 24 h. (e) Representative FACS plots showing gated RFP+ neutrophils. Monocytes, macrophages, dendritic cells (DCs) and T/B cells 24 h after i.v. injection of 10⁷ *T. gondii* ME49-RFP tachyzoites. (f) Enumeration of RFP+ cell types shown in (e). (g) Representative histograms of cell type-specific gated RFP+ and RFP− cells showing expression levels of ASC (left panels) or FAM-YVAD (right panels) 24 h after i.v. injection with 10⁷ *T. gondii* ME49-RFP tachyzoites. FMO control for ASC panels are cells from infected animals that did not get stained with anti-ASC-Alexa488 but all other antibodies. FMO control for FAM-YVAD are cells from mice that were injected with *T. gondii* ME49-RFP but did not receive an injection with FLICA FAM-YVAD. MFI values ± SD for FAM-YVAD expression in RFP+ and RFP− neutrophils, monocytes and DCs from three mice shown in table. Results are presented as individual data points (d,f), pooled data means ± SEM (a,b) and representative FACS plots (c,e) and histograms (g) of 6–9 mice from two or three pooled independent experiments. Statistical analyses: One-way ANOVA followed by Dunnett’s multiple comparison test (a) or Student’s t-test (b,d,g); significant differences are indicated by asterisks: *p < 0.05; **p < 0.01; ***p < 0.001.

IL2C pre-treatment protects mice from acute lethal toxoplasmosis independently of T<sub>Reg</sub> expansion and parasite burden. To definitively assess if IL2C-mediated expansion of IL-18-responsive IFN-γ-secreting non-CD4 cell subsets can prevent lethal toxoplasmosis in mice, we used the well-established oral inoculation model with *T. gondii* ME49 bradyzoite-containing brain cysts. As above, naïve B6 mice were treated i.p. with IL2C for four consecutive days (Fig. 7a). IL2C treatment was accompanied by a weight loss from which mice recovered within a few days (data not shown). Forty-eight hours after the last IL2C treatment, mice were inoculated orally with 10 or 40 *T. gondii* ME49 cysts and were assessed for weight loss and consequent survival, whereby mice were euthanized when weight loss exceeded 20% of body weight, in accordance with Animal Ethics Committee of James Cook University Approvals A2138 and A2324. All mice that had been inoculated with 40 cysts and 87% of mice that had been inoculated with 10 cysts, but had not received IL2C injections, succumbed within 14 days after inoculation (Fig. 7b,c). In contrast, IL2C pre-treatment extended survival in mice that had been inoculated with 40 cysts up to 36 days, and approximately 40% of mice that had been inoculated with 10 cysts survived until day 60 (Fig. 7b,c).
Importantly, depletion of NK cells, CD8+ T cells, Thy1.2+ cells (expressed on all T cells and immature NK cells) or IFN-γ from mice that had been treated with IL2C for four days and had been inoculated with 10^7 T. gondii ME49 cysts with neutralizing antibodies reversed IL2C-mediated increase in survival (Fig. 7d,e), indicating that IL2C-mediated cell expansion directly correlated with increased survival. Similarly, neutralization of IL-18, IL-12 or IFN-γ reversed the protective phenotype (Fig. 7d,f). All mice that were not treated with IL2C succumbed to the infection by day 16, with a median survival of 11 days (Fig. 7f). Whilst 67% of IL2C-treated mice that received control rat IgG survived until day 60, the median survival for mice treated with anti-IFN-γ was 10.5 days, 13 days for mice treated with anti-IL-12 and 14 days for mice treated with anti-IL-18 (Fig. 7f). All mice that survived until day 60 were assessed for T. gondii brain cysts and all contained cysts in their brain, indicating that all cells were infected and that survival was not due to a failure of the infection to establish.

To assess if IL2C pre-treatment also impacts on measurable disease parameters other than survival, we also assessed pathology, parasite burden, serum cytokine levels and TReg numbers in MLN and lamina propria (LP). In all groups, parasite burden was below detection limits in IL2C-treated and untreated animals at 2 days after infection and progressively increased at the same rate in both groups through days 4 and 9 post-infection (Fig. 7i). Due to the low infectious dose of 10 cysts, inflammatory cytokines such as IFN-γ, IL-6, IL-12 and TNF were not significantly reduced gross pathology of gut and liver (Fig. 7g,h) in the absence of any effect on parasite burden (Fig. 7i); and progressively increased at the same rate in both groups through days 4 and 9 post-infection (Fig. 7i). Due to the low infectious dose of 10 cysts, inflammatory cytokines such as IFN-γ, IL-6, IL-12 and TNF were not detectable in any mice at 2 and 4 days after infection and, although detectable at day 9 post-infection, there was no significant difference in the levels of these cytokines in IL2C-treated versus untreated mice (data not shown). Similarly, systemic IL-10 levels (Fig. 7j) and TReg numbers in MLN and lamina propria were not increased by IL2C pre-treatment (Fig. 7k–m) suggesting a role for IL2C pre-treatment independent of the previously reported IL2C-mediated increase in survival (Fig. 7d,e).

To assess if IL2C pre-treatment also impacts on measurable disease parameters other than survival, we also assessed pathology, parasite burden, serum cytokine levels and TReg numbers in MLN and lamina propria (LP) at 2, 4 and 9 days following oral cyst infection. At 9 days after infection, IL2C pre-treatment mice displayed significantly reduced gross pathology of gut and liver (Fig. 7g.h) in the absence of any effect on parasite burden (Fig. 7i); thus, parasite burden was below detection limits in IL2C-treated and untreated animals at 2 days after infection and progressively increased at the same rate in both groups through days 4 and 9 post-infection (Fig. 7i). Due to the low infectious dose of 10 cysts, inflammatory cytokines such as IFN-γ, IL-6, IL-12 and TNF were not detectable in any mice at 2 and 4 days after infection and, although detectable at day 9 post-infection, there was no significant difference in the levels of these cytokines in IL2C-treated versus untreated mice (data not shown). Similarly, systemic IL-10 levels (Fig. 7j) and TReg numbers in MLN and lamina propria were not increased by IL2C pre-treatment (Fig. 7k–m) suggesting a role for IL2C pre-treatment independent of the previously reported TReg expansion with JES6-1A12-containing IL2C40,41. Collectively, these results demonstrate a protective role of IL2C pre-treatment in acute lethal murine toxoplasmosis that is dependent on IL-12, IL-18 and IFN-γ but is independent from effects on parasite burden.

**Discussion**

Non-CD4 cells, such as CD8+ T cells, DN T cells and NK cells, have been implicated in early control of severe infections with intracellular pathogens, including T. gondii, M. tuberculosis and Salmonella29. Our study provides a mechanistic framework for how T. gondii activates IFN-γ secretion by protective CD8+ T cells, DN T cells and NK cells. In particular, we demonstrate that in vivo IL-18-driven IFN-γ secretion in response to T. gondii likely requires the activation of at least three different inflammasomes. The involvement of both NLRP1 and NLRP3 has been shown in other, distinct models of toxoplasmosis24 but, in the model presented here, only Caspase1/11−/− mice but not Nlrp1−/−, Nlrp3−/− and Nlrp1−/−Nlrp3−/− mice were devoid of circulating IL-18 after T. gondii infection. These results suggest that a third sensor for in vivo T. gondii detection must exist in addition to NLRP1 and NLRP324,42. This conclusion is underscored by the fact that Caspase1/11−/− mice but not Nlrp1−/−, Nlrp3−/− and Nlrp1−/−Nlrp3−/− mice all maintained significant levels of IFN-γ+ NK cells after 24 h infection.
with *T. gondii*. Furthermore, we show that inflammasome activation occurred in CD8α+ DCs, inflammatory monocytes and neutrophils, cell types that have also been implicated in IL-12 secretion in response to *T. gondii*. These results imply a high level of redundancy in the cell type that senses *T. gondii* infection as well as in the host IL-12 production.

**Figure 6.** IL2C treatment expands IL-18-responsive IFN-γ-secreting cell subsets. (a) Experimental plan showing that naïve B6 mice were treated i.p. with IL2C on four consecutive days. One day after the last administration, some mice were euthanized to isolate cells from spleens, mesenteric lymph nodes (MLN) and Peyer’s Patches (PP). Other mice were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites 2 days after the last IL2C treatment and cells were isolated 24 h later. (b–d) Numbers of CD3⁺CD8⁺, CD3⁺CD4⁺CD8⁻ (DN) and CD3⁻ NKp46⁺ cells (enumerated by FACS) in spleens (b), MLN (c) and PP (d) of naïve B6 mice that were treated i.p. with IL2C on four consecutive days and euthanased 1 day after the last administration. (e,f) Proportions (e) and total numbers (f) of CD3⁻NKp46⁺ CD3⁺CD4⁺, CD3⁺CD8⁻ and CD3⁺CD4⁻CD8⁻ (DN) IFN-γ⁺ cells (assessed by FACS) in spleens of B6 mice that were treated i.p. with IL2C on four consecutive days and, 2 days after the last IL2C treatment, were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites and cells isolated 1 day later. (g,h) IFN-γ (g) and IL-18 (h) serum concentrations of B6 mice that were treated i.p. with IL2C on four consecutive days and, 2 days after the last IL2C treatment, were injected i.v. with 10⁷ *T. gondii* ME49 tachyzoites and serum collected 1 day later. (i,j) Expression of IL18R (i) and IL12R (j) on IFN-γ⁻ (blue histogram) and IFN-γ⁺ CD3⁻NKp46⁺ cells after i.v. infection with 10⁷ *T. gondii* ME49 tachyzoites with (orange histogram) or without (red histogram) IL2C treatment. Results are presented as pooled data means ± SEM from at least two pooled independent experiments with 5–6 mice per group (b–d, e,f), with individual data points shown for (g,h), and as representative histograms and individual data points of mean fluorescent intensity for (i,j). Statistical analyses: One-way ANOVA followed by Dunnett’s multiple comparison test (a,b,c,d,e,f); significant differences are indicated by asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. not significant.
**Figure 1.**

(a) Overview of the experimental design: Mice were treated with i.p. IL2C on d-5, d-2, and d0 p.o. ME49 cysts. d60 survival brain cysts were assessed.

(b) Percent survival over time for different groups: IL2C (n=7), 40 cysts (n=15), 40 cysts + IL2C (n=14).

(c) Percent survival over time for different groups: 10 cysts (n=15), 10 cysts + IL2C (n=15).

(d) Treatment regimens: i.p. IL2C on d-5, d-2, and d0 p.o. ME49 cysts. d60 survival brain cysts were assessed.

(e) Percent survival over time for different groups: 10 cysts (n=10), 10 cysts + IL2C + rat IgG (n=15), 10 cysts + IL2C + anti IL12 (n=10), 10 cysts + IL2C + anti IL18 (n=9), 10 cysts + IL2C + anti IFNγ (n=10), 10 cysts + IL2C + anti CD8 (n=10), 10 cysts + IL2C + anti Thy1.2 (n=10).

(f) Percent survival over time for different groups: 10 cysts (n=10), 10 cysts + IL2C + anti IFNγ (n=10), 10 cysts + IL2C + anti CD8 (n=10), 10 cysts + IL2C + anti Thy1.2 (n=10).

(g) Score comparison: Naive vs. ME49 vs. IL2C + ME49.

(h) Score comparison: Naive vs. ME49 vs. IL2C + ME49.

(i) Parasite burden: Naive ME49 vs. IL2C + ME49.

(j) IL-10 [ng/ml]: Naive ME49 vs. IL2C + ME49.

(k) Flow cytometry analysis: CD25Fox3 cells/MLN [10^5].

(l) Flow cytometry analysis: CD25Fox3 cells/LP [10^5].

(m) Flow cytometry analysis: CD25Fox3 cells/LP [10^5].
inflammasome signaling pathway. This is in contrast to the often very specific recognition of viral and bacterial infections by one particular inflammasome in a distinct cell type. It is likely that this divergence highlights the evolutionary complexity of parasites and suggests that more highly evolved organisms have developed a more complex inflammasome-dependent interplay with their hosts. In line with this hypothesis, it was shown recently in vitro that *T. gondii* also activates the NLRC4 and AIM2 inflammasomes in human fetal small epithelial cells, as well as the expression of NLRP6, NLRP8 and NLRP13 in THP-1 macrophages. Given that myeloid cell subsets often express distinct arsenals of PRRs on the cell surface and intracellularly, their ability to recognize and interact with *T. gondii* differs. Subsequently, the identification and characterization of distinct myeloid cell types producing IL-18 in response to *T. gondii* may foster innovative strategies for targeted interventions.

Toxoplasma gondii appears to activate both NLRP1 and NLRP3, yet the specificity of this activation remains elusive. While NLRP3 activation in response to *T. gondii* is influenced by P2X<sub>7</sub>, receptor-dependent potassium efflux and the induction of reactive oxygen species, the exact mechanisms of how *T. gondii* activates multiple inflammasomes remain enigmatic. It is also interesting to note that in vitro infection of mouse macrophages and human monocytes with *T. gondii* only leads to the secretion of IL-1β, but not IL-18. In contrast, in vivo infection in mice leads to significant secretion of IL-18 but not IL-1β. It has even been suggested that in vitro infection of human neutrophils leads to evasion of NLRP3 activation and IL-1β secretion. Furthermore, in vitro activation of inflammasomes differs between *T. gondii* strains, and is predominantly induced by Type II parasites. These findings suggest that *T. gondii* has evolved sophisticated diverging effector mechanisms to manipulate inflammasome biology in different host cell subsets, and suggest that secreted effector molecules and/or distinct structural proteins may underlie inflammasome activation. It is, therefore, interesting that *Nlrp1<sup>−/−</sup>*/*Nlrp3<sup>−/−</sup> mice did not show reduced IL-18 secretion after infection with *T. gondii*. It is important to note that in mice the *Nlrp1* locus is on the same chromosome as the *Nlrp3* gene, meaning that the generation of rare double knockout offspring relies on recombination rather than inheritance. It will therefore be important to further investigate the role of Nlrp1 and 3 with alternative methods, such as CRISPR/Cas9 and/or chemical inhibition.

Our study has ruled out ASP5-dependent GRA proteins, the most abundant family of *T. gondii*-derived effector molecules, as the primary activator of inflammasomes. GRA molecules influence several host cell pathways and are required for the transport of small molecules across the parasitophorous vacuole. These results do not exclude GRA proteins that don’t depend on ASP5 for export, and further studies will have to investigate the role of ASP5-independent GRA proteins as well as rheopy proteins and other surface structures in driving this process. In particular, the recently described MYR1 protein export system may be valuable in answering if secreted effector molecules are at all required to initiate inflammasome activation.

It is tempting to speculate that the overall purpose of activating multiple inflammasomes in multiple cell types is to drive an inflammatory host response that mediates the progression of *T. gondii* into the chronic cyst phase, while at the same time preventing activation of parasite-killing mechanisms. *Toxoplasma* can invade and replicate in virtually all nucleated cell types of warm-blooded animals. From an evolutionary perspective, it is not surprising that the arms race between the host and the parasite has led to the evolution of numerous strategies to activate the immune system (from the parasite’s perspective) and to sense the invasion (from the host’s perspective). The fundamental differences between the habitats and the composition of the immune system of susceptible warm-blooded host species may require *T. gondii* to activate as many different inflammasome sensors as possible. It is well established that *T. gondii* requires a pro-inflammatory, IFN-γ-dominated immune response to form cysts. Because transmission is critical for the parasite’s survival and completion of the life cycle, it is maladaptive for *T. gondii* to kill its host. This may explain why IFN-γ neutralization is fatal, because IFN-γ deficiency favors tachyzoite replication and prevents cyst formation. Furthermore, these findings may also explain why *T. gondii* cysts reactivate after HIV co-infection in humans; HIV destroys CD4<sup>+</sup> T cells, a prime IFN-γ producer. Hence, we reasoned that a viable adjunct therapy in *T. gondii* HIV co-infection might be achieved by boosting IFN-γ-producing NK cells, CD8<sup>+</sup> T cells and DN T cells to prevent acute toxoplasmosis.
Interleukin-2 and interleukin-15 are critical cytokines for the maturation and survival of IL-18 responsive DN T cells, NK cells and CD8+ T cells. The role of IL-15 in immunity to *T. gondii* remains controversial, but IL-2 knockout mice are highly susceptible to *T. gondii* infection and injection of recombinant IL-2 enhances survival of toxoplasma-infected mice. Because IL-2 and IL-15 signaling depends on trans-presentation, complexing IL-2 with anti-IL-2 (IL2C) or IL-15 with IL-15RaF (IL15C) significantly enhances their biological activity in vivo. Importantly, the binding site of the anti-IL2 clone used in the IL2C determines whether a preferential expansion of regulatory T cells (T\textsubscript{reg}) anti-IL-2 clone JES6-1A12) or CD8+ T cell, NK cells and DN T cells occurs (anti-IL-2 clone S4B6). Using JES6-1A12-containing IL2C, Akbar et al. showed that selective expansion of T\textsubscript{reg} cells in Type 1 *T. gondii* RH-infected animals improved control of the parasite. It was also demonstrated that T\textsubscript{reg} expansion with JES6-1A12-containing IL2C can overcome the competition for bioavailable IL-2 by regulatory and effector T cells, leading to reduced immunopathology and morbidity during acute Type II *T. gondii* ME49 infection. These studies are in line with other reports showing a collapse of T\textsubscript{reg} cells during acute *T. gondii* infection due to IL-2 starvation and an overall protective role of T\textsubscript{reg} in acute *T. gondii*-mediated immunopathogenesis. In contrast to JES6-1A12-containing IL2C, S4B6-containing IL2C has been shown to boost NK cell and memory CD8+ T cell numbers in mice and to enhance their cytolytic capacity against viral infections, malaria and cancer cells. Short-term exposure of naïve mice to IL2C containing S4B6 has also been shown to enhance resistance and immunity against *Listeria monocytogenes* infection. Our study is the first to show a protective effect of S4B6-containing IL2C pre-treatment in toxoplasmosis and our results suggest that IL2C pre-treatment can protect mice from lethal toxoplasmosis via different mechanisms, depending on the IL-2 mAb clone used to prepare the cytokine complex. Thus, JES6-1A12-containing IL2C seems to compensate for the limited bioavailability of IL-2 for Treg survival during acute *T. gondii* infection, leading to reduced immunopathology, whereas S4B6-containing IL2C protects whilst also reducing pathological features in a Treg-independent manner. Our findings do not definitively rule out a role for Treg function or local (i.e., gut) IL-10 in SB46 IL2C treated mice (e.g., via use of Treg or IL-10 depleted or knockout mouse) but our results do show that S4B6 IL2C treatment has no effect on systemic IL-10 levels, further pointing towards a Treg-independent function. Based on our results, we conclude that S4B6-containing IL2C seems to favor survival and expansion of IL-18 driven IFN-γ secretion, possibly driving parasites towards stage conversion and cyst formation. It is, hence, tempting to speculate that both types of IL2C could have a synergistic effect if applied together.

Cytokine complex-mediated immunotherapy has not only attracted attention in models of infectious diseases but also in the cancer field. IL2C treatment reduces viral load in a mouse model of gamma-herpesvirus infection and impacts positively on mouse melanoma and BCL1 leukemia. More recently, IL2C treatment has also been tested successfully in cancer models in combination with immune checkpoint blockade. IL-15/IL-15RaF complexes (IL15C) have also been shown to expand CD8+ T cell, DN T cell and NK cell populations, and to protect mice against cerebral malaria via the induction of IL-10-producing NK cells. Whether IL15C would also be protective in our model of lethal toxoplasmosis remains to be investigated. Taken together, these results suggest that cytokine complex treatment may be a more broadly applicable adjunct therapy in infectious diseases, but also highlight that the protective mechanisms may differ between different pathogens and cytokine complex types used. To our knowledge, no data are available yet on any clinical use of IL2C and IL15C in humans. It will be important to consider the hyper-inflammatory response that can be attributed to IL2C and IL15C treatment and, hence, careful consideration should be taken before using cytokine complexes clinically in the context of toxoplasmosis.

In summary, here we delineate a mechanistic framework for how IFN-γ is produced by non-CD4 cell types in vivo in response to *T. gondii*, including a crucial role for parasite viability and inflammammasome-dependent IL-18 secretion. Our results demonstrate that in vivo inflammammasome activation in response to *T. gondii* occurs in multiple myeloid cell types and indicate the existence of an unidentified *T. gondii*-sensing component. Additionally, our study excludes *T. gondii*-derived, ASP5-dependent, dense granule proteins as the main activators of inflammammasomes in vivo. The observation that both IL-12 and IL-18 neutralization reverses the host protective role of *T. gondii*-derived, ASP5-dependent, dense granule proteins as the main activators of inflammammasomes in vivo. The observation that both IL-12 and IL-18 neutralization reverses the host protective role of *T. gondii*-mediated inflammasome activation in response to *T. gondii* infection, leading to reduced immunopathology, whereas S4B6-containing IL2C protects whilst also reducing pathological features in a Treg-independent manner. Our findings do not definitively rule out a role for Treg function or local (i.e., gut) IL-10 in SB46 IL2C treated mice (e.g., via use of Treg or IL-10 depleted or knockout mouse) but our results do show that S4B6 IL2C treatment has no effect on systemic IL-10 levels, further pointing towards a Treg-independent function. Based on our results, we conclude that S4B6-containing IL2C seems to favor survival and expansion of IL-18 driven IFN-γ secretion, possibly driving parasites towards stage conversion and cyst formation. It is, hence, tempting to speculate that both types of IL2C could have a synergistic effect if applied together.

Cytokine complex-mediated immunotherapy has not only attracted attention in models of infectious diseases but also in the cancer field. IL2C treatment reduces viral load in a mouse model of gamma-herpesvirus infection and impacts positively on mouse melanoma and BCL1 leukemia. More recently, IL2C treatment has also been tested successfully in cancer models in combination with immune checkpoint blockade. IL-15/IL-15RaF complexes (IL15C) have also been shown to expand CD8+ T cell, DN T cell and NK cell populations, and to protect mice against cerebral malaria via the induction of IL-10-producing NK cells. Whether IL15C would also be protective in our model of lethal toxoplasmosis remains to be investigated. Taken together, these results suggest that cytokine complex treatment may be a more broadly applicable adjunct therapy in infectious diseases, but also highlight that the protective mechanisms may differ between different pathogens and cytokine complex types used. To our knowledge, no data are available yet on any clinical use of IL2C and IL15C in humans. It will be important to consider the hyper-inflammatory response that can be attributed to IL2C and IL15C treatment and, hence, careful consideration should be taken before using cytokine complexes clinically in the context of toxoplasmosis.

In summary, here we delineate a mechanistic framework for how IFN-γ is produced by non-CD4 cell types in vivo in response to *T. gondii*, including a crucial role for parasite viability and inflammammasome-dependent IL-18 secretion. Our results demonstrate that in vivo inflammammasome activation in response to *T. gondii* occurs in multiple myeloid cell types and indicate the existence of an unidentified *T. gondii*-sensing component. Additionally, our study excludes *T. gondii*-derived, ASP5-dependent, dense granule proteins as the main activators of inflammammasomes in vivo. The observation that both IL-12 and IL-18 neutralization reverses the host protective role of CD8+ T cells, DN T cells and NK cell-produced IFN-γ during *T. gondii* infection highlights the redundancy and functional interchangeability of both cytokines during *T. gondii* infection. This combination of observations led us to the hypothesis that enhancement of inflammammasome-dependent, IL18-driven production of IFN-γ by non-CD4 cells may be a route to control acute toxoplasmosis in AIDS. In accord with this, we provide compelling evidence for a protective role of IL2C pre-treatment in lethal toxoplasmosis. We demonstrate that IL2C-mediated expansion of CD8+ T cells, NK cells and DN T cells protects mice against acute disease and death in an IFN-γ-dependent manner. Hence, we conclude that inducing immune responses that lead to the expansion of IFN-γ-secreting CD8+ T cells, DN T cells and NK cells could be a crucial feature of improved toxoplasmosis intervention strategies, perhaps most particularly in the context of HIV co-infection and AIDS.

**Methods**

**Mice.** C57BL/6 J and Arc(S) mice were purchased from the Animal Resource Center (Perth, Australia). Knockout mice (*Caspass1*1/-, *Nlrp1*-/-, *Nlrp3*-/- and *Il18*1/-) were bred and maintained at the Australian Institute of Tropical Health and Medicine, James Cook University, Cairns and Townsville, Australia. Double knockout mice (*Nlrp1*-/-*Nlrp3*-/-) were bred by sequentially crossing *Nlrp1*-/- and *Nlrp3*-/- mice. Genotyping was performed using the following primer pairs: *Nlrp3*-F 5′-GCTCAGGACATCGTCTGGA-3′, *Nlrp3*-R 5′-TGAAGTTCCACATCTTCAAGG-3′, *Nlrp3*-R 5′-TTGTAGTTGCGCTGTGTGGCTT-3′, *NIP1* WT: *Nalp1a* F 5′-TGGAGGAGGCGAAGCTTTA-3′, *Nalp1aR* 5′-ACCCAGGGAACCTCACACAG-3′; *NIP1* mutant: *Nalp1a* F 5′-TGTAGAGTTCGAGGAAAA-3′, *Nalp1aR* 5′-GAGAGACTCCACACCTAA-3′. The following mice were used for experiments: *Nlrp1*-/-*Nlrp3*-/-, *Nlrp1+/-Nlrp3*-/- and *Nlrp1-/-Nlrp3+/-*. For infection
experiments, all mice were sex- and age-matched, and kept in our BSL 2 animal facility under specific pathogen-free (SPF) conditions.

**Parasites.** Type II *T. gondii* strains ME49, ME49-RFP, ME49 GRA20-deficient, ME49 GRA23-deficient, ME49 ASP5-deficient and DEG (ATCC, ATCC30855) were maintained by continuous passage in human foreskin fibroblasts (HFF; ATCC, ATCCSCRC1041) in DMEM supplemented with 10% FCS, penicillin, streptomycin and L-glutamine at 37 °C and 5% CO₂. Parasites were harvested from recently lysed cell monolayers, passed through a 26G needle and a 3 μm TSTP Isopore™ membrane filter and concentrated by centrifugation at 500 g for 10 min. The pellet of tachyzoites was re-suspended in sterile PBS. Parasites were counted using a Neubauer hemocytometer and diluted to the required infectious dose in sterile PBS.

**Generation of *T. gondii* ME49 *Gra20* and *Gra23* knockouts.** We employed a CRISPR/Cas9 approach to insert frameshifts within the first 20 nt of the start of the coding sequence of *gra20* and *gra23* in *T. gondii* ME49 with consequential disruption of the final translated proteins. Inverse PCR was used to exchange the sgRNA of UPRT with the sgRNA for GRA20 with Ph-sgRNA_TgGRA20mutF (5’-ATG CAT AGC CGG AAC TGC GTG TTT TAGAGCTGAAAATAGC-3’) and Ph-genCas9mutR (5’-AACTTGACATGCCCATTTAC-3’) to yield plasmid pCAS9sgGRA20. Similarly, inverse PCR was used to exchange the sgRNA of UPRT with the sgRNA for GRA23 with Ph-sgRNA_TgGRA23mutF (5’-GCAGGCGGTGGGAAAGCAGGTGTTTAGAGCTGAAATAGC-3’) and Ph-genCas9mutR (5’-AACTTGACATGCCCATTTAC-3’) to yield plasmid pCAS9sgGRA23. Transfection of *T. gondii* ME49 was carried out as described previously⁹⁸. Twenty-four hours post-transfection, transiently transfected GFP⁺ parasites were purified by flow cytometry as previously described⁹⁰ and individual GRA20 and GRA23 KO clones were further purified using two rounds of limiting dilution cloning. Sanger sequencing of PCR products was used to confirm disruption of the *gra20* and *gra23* ORFs.

**Infections and monitoring.** To isolate *T. gondii* ME49 bradyzoite containing cysts, the brains of chronically infected Arc(S) mice (injected i.p. with 500 tachyzoites of *T. gondii* ME49 > 8 weeks prior) were removed, homogenized in sterile PBS, and subjected to centrifugation in a discontinuous Percoll gradient. Cysts were counted using a Neubauer hemocytometer and diluted in sterile PBS. For experiments, B6 mice were inoculated with 10, 40 or 100 cysts by oral inoculation. For mechanistic studies, B6 mice were injected i.v. in the lateral tail vein with 10⁷ tachyzoites of *T. gondii* ME49, mutant strains on the *T. gondii* ME49 background or the Type II strain *T. gondii* DEG in a volume of 200 μl. For heat inactivation, *T. gondii* ME49 tachyzoites were grown as described above, enumerated, and washed twice with PBS before incubation at 62°C in a water bath for 1 h. Effective killing was verified by addition of heat-killed parasites to a HFF cell monolayer.

All mice were monitored as stipulated by Animal Ethics Committee of James Cook University Approvals A2138, A2324. Chronically infected Arc(S) mice were monitored weekly for signs of morbidity and were euthanized using carbon dioxide asphyxiation for brain cyst harvesting. Mice infected orally with *T. gondii* ME49 were monitored daily for signs of disease and were euthanized using carbon dioxide asphyxiation to 72 h after infection.

**Isolation of leukocytes.** Spleens, mesenteric lymph nodes and Peyer’s Patches were extracted and mechanically disrupted by pushing cells through a 70 μm cell strainer. Cells were pelleted at 1500g for 10 min. Spleens were removed and single-cell suspensions were made by passing through a 70-μm cell strainer. Cells were pelleted at 1500g, and then resuspended in RPMI 1,640 containing 5% FCS at a concentration of 1 × 10⁷ cells/ml. Two hundred microliters of spleen cell suspension was added to the first well of a 96-well plate and then serially diluted 1/2 across the plate. Plates were incubated at 37 °C in 5% CO₂ for 7 days before wells...
were examined for the presence of parasites. A score of parasite burden was allocated based on the last column in which parasites were visible.

**Flow cytometry.** To assess expression of surface antigens and IFN-γ secretion, viable, red blood cell-depleted single-cell suspensions were stained with monoclonal antibodies (all from BD Pharmingen) against CD4 (clone GK1.5), CD8a (clone 53-67), CD3 (clone 145-2C11), NKp46 (clone 29A1.4), CD44 (clone 1M7), CD90.1 (clone 30-H12), CD11b (clone M1/70), CD11c (clone HL3), MHC-II (clone M5/114), Ly6G (clone 1A8), Ly6C (clone AL-21), CD19 (clone ID3), F4/80 (clone BM8), or IFN-γ detection antibody (Miltenyi Biotec, Germany), IL-18Ralpha (R&D Systems) or IL-12Rbeta1 (CD212, BD). CD3⁺CD4⁺CD25⁺Foxp³⁺ regulatory T cells were identified using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). After washing the cells, samples were analyzed using a FACSCompII or FortessaX20 analyzers (BD Biosciences, CA). Propidium iodide (2 µg/ml) or Fixable Viability Dye e780 (BD) was added to exclude dead cells. Flow cytometry data were analyzed using FlowJo software (Treestar, CA). For all flow cytometry-based analyses, cells were first gated on singlets, followed by dead cell exclusion, scatter characteristics and surface marker expression. All samples contained Blank Calibration Particles (BD) to allow cell enumeration.

**Assessment of ex vivo IFN-γ secretion.** Ex vivo IFN-γ secretion by distinct lymphocyte subsets was assessed as described previously39, Briefly, mice were injected i.v., i.p., or p.o. with different doses of *T. gondii* ME49 cysts or tachyzoites (as described in figure legends). At different time points after injection of parasites (as described in figure legends), organs were removed aseptically, single cell suspensions were prepared and red blood cells were lysed. Cells (10⁶) were stained with the ‘Mouse IFN-γ secretion assay detection kit’ (Miltenyi Biotec, Germany) according to the manufacturer's instructions and IFN-γ secretion was analyzed by flow cytometry. Cells were first gated on live, single lymphocytes, followed by separation into CD3⁺Ly6C⁻ and CD3⁺Ly6C⁺ cells. CD3⁺Ly6C⁻ cells were further gated into CD4⁺, CD8⁺ and CD4⁺CD8⁻ subsets. CD3⁺Ly6C⁺, CD3⁻NK1.1⁺CD4⁺, CD3⁻NK1.1⁻CD8⁺ and CD3⁻NK1.1⁻CD4⁻CD8⁻ cells were assessed for IFN-γ secretion.

**Detection of in vivo inflammasome activation by flow cytometry.** Detection of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) assembly was performed as described previously40. Briefly, mice were injected with 10⁷ *T. gondii* ME49-RFP tachyzoites and euthanased 24 h later. Cells were stained for surface molecules, fixed, permeabilized and stained with rabbit anti-ASC antibody (Santa Cruz Biotechnology) for 45 min at room temperature. Subsequently, a secondary anti-rabbit Alexa488 antibody (Life Technologies) was added for 5 min at room temperature. A FMO control without anti-goat Alexa488 was included.

Detection of active caspase-1 by flow cytometry was performed using the carboxyfluorescein FLICA kit (FAM-YVAD-FMK, Immunochemistry Techniques, Bloomington, MN). B6 mice were injected with 10⁷ *T. gondii* ME49-RFP tachyzoites and 23 h later FAM-YVAD-FMK (diluted in DMSO and PBS) was injected intravenously. Splenic cells were analyzed by FACS 1 h later as described above (24 h after *T. gondii* ME49-RFP injection). Mice that received *T. gondii* ME49-RFP but no FAM-YVAD-FMK were used as FMO control.

Single cells were gated for RFP expression and RFP⁺ cells were analyzed for expression of neutrophil, macrophage, monocyte, dendritic cell, T cell and B cell specific surface markers and positivity in green fluorescence as shown in Fig. 4.

**Multiplex and ELISA.** Blood for serum analysis was taken post mortem from the aorta abdominis and collected in serum separator tubes (BD), left for 30 min at room temperature, followed by centrifugation at 12,000 g for 3 min. Sera were stored at –20 °C until analysis. Measurements were performed using CBA (BD Biosciences, CA) or ELISA (elisakit.com, Australia) according to manufacturers' instructions. Samples were acquired on a FACSCompII (BC Biosciences, CA) or FLUOstar Omega ELISA Reader (BMG Labtech).

**IL-2/anti-IL-2 complex-mediated cell expansion.** IL-2/anti-IL-2 complexes (IL2C) were prepared as described previously41. Briefly, 1.5 µg of recombinant mouse IL-2 (Peprotech) and 10 µg of anti-IL-2 mAb (clone S4B6, Walter and Eliza Hall Institute [WEHI] antibody facility, Melbourne, Australia) were mixed, incubated at 37 °C for 30 min, and administered i.p. in a volume of 200 µl for four consecutive days. Mice were monitored and weighed daily during the IL2C treatment period.

**Antibody-mediated cell depletion and cytokine neutralization.** For cytokine neutralization and cell depletion, monoclonal antibodies against IL-12, IL-18, IFN-γ, CD8, NK1.1, Thy1.2 and rat IgG were purchased from the WEHI antibody facility or from BioXCell (NH, USA). A total of 200 µg of anti-IL-18 (clone YIGIOT4-1G7; Cat. No.: BE0237), anti-IFN-γ (clone HB170-15), anti-IL12 (clone C17.8), anti-NK1.1 (clone PK136), anti-CD8 (clone 2.43), anti-Thy1.2 (clone 30H12) or control rat IgG were injected i.p. weekly in a volume of 200 µl.

**Statistics.** Statistical analysis was performed using GraphPad Prism, GraphPad software, San Diego, CA as indicated in individual figure legends. These included: one-way analysis of variance (ANOVA), followed by Dunnett’s multiple comparison test for most data sets; two-way ANOVA followed by Tukey’s post hoc test for data presented in Fig. 3; two-tailed Student’s t tests for data presented in Fig. 7i; a Log-rank (Mantel–Cox) test
to compare significance for survival experiments in Figs. 7b,c,e. A P value of less than 0.05 was considered significant.

**Ethics statement.** All experiments were approved and conducted according to Australian animal protection law and in accordance with requirements of the Animal Ethics Committee of James Cook University (Approvals A2138, A2324). Death was never used as an endpoint.

**Data availability** All data are available within the manuscript and Supplementary Information.

Received: 18 April 2019; Accepted: 23 July 2020

**References**

1. Seebre, F. & Steinfelder, S. Recent advances in understanding apicomplexan parasites. F1000Research https://doi.org/10.12688/f1000research.7924.1 (2016).
2. Yarovinsky, F. Innate immunity to Toxoplasma gondii infection. Nat. Rev. Immunol. 14, 109–121. https://doi.org/10.1038/nri3598 (2014).
3. Zhang, Y., Lin, X. & Lu, F. Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis. Acta Trop. 185, 52–62. https://doi.org/10.1016/j.actatropica.2018.04.026 (2018).
4. Fallahi, S., Rostami, A., Nourollahpour Shiadeh, M., Behniafar, H. & Paktinat, S. An updated literature review on maternal-fetal and reproductive disorders of Toxoplasma gondii infection. J. Gynecol. Obstet. Reprod. 47, 133–140. https://doi.org/10.1016/j.jogoh.2017.12.003 (2018).
5. Dard, C. et al. Management of toxoplasmosis in transplant recipients: An update. Expert Rev. Anti Infect. Ther. https://doi.org/10.1080/14787210.2018.1483721 (2018).
6. Rajapakse, S., Weeratunga, P., Rodrigo, C., de Silva, N. L. & Fernando, S. D. Prophylaxis of human toxoplasmosis: A systematic review. Pathog. Glob. Health 111, 333–342. https://doi.org/10.1080/20477724.2017.1370528 (2017).
7. Sturge, C. R. & Yarovinsky, F. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection. Infect. Immun. 82, 3090–3097. https://doi.org/10.1128/ai.01722-14 (2014).
8. Scharton-Kersten, T. M., Magram, J. & Sher, A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 185, 1261–1273 (1997).
9. Scharton-Kersten, T. M. et al. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157, 4045–4054 (1996).
10. Suzuki, Y., Orellana, M. A., Schreiber, R. D. & Remington, J. S. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240, 516–518 (1988).
11. Gazzinelli, R., Xu, Y., Hiens, S., Cheever, A. & Sher, A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. F1000Research 7, 924.1 (2016).
12. Suzuki, Y., Orellana, M. A., Schreiber, R. D. & Remington, J. S. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240, 516–518 (1988).
13. Hunter, C. A., Subauste, C. S., Van Cleave, V. H. & Remington, J. S. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect. Immun. 62, 2818–2824 (1994).
14. Denkers, E. Y., Gazzinelli, R. T., Martin, D. & Sher, A. Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MH Class I-deficient mice. J. Exp. Med. 178, 1465–1472 (1993).
15. Yarovinsky, F. et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308, 1626–1629. https://doi.org/10.1126/science.1109893 (2005).
16. Plattner, F. et al. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. Cell Host Microbe 3, 77–87. https://doi.org/10.1016/j.chom.2008.01.001 (2008).
17. Scanga, C. A. et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 168, 5997–6001 (2002).
18. Hou, B., Benson, A., Kuzmich, L., DeFranco, A. L. & Yarovinsky, F. Critical coordination of innate immune defense against Toxoplasma gondii by dendritic cells responding via their Toll-like receptors. Proc. Natl. Acad. Sci. USA 108, 278–283. https://doi.org/10.1073/pnas.101549108 (2011).
19. LaRosa, D. F. et al. T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc. Natl. Acad. Sci. USA 105, 3853–3860. https://doi.org/10.1073/pnas.070663105 (2008).
20. Sun, J. & Lanier, L. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat. Rev. Immunol. 11, 645–657 (2011).
21. O’Donnell, H. et al. Toll-like receptor and inflammasome signals converge to amplify the innate bactericidal capacity of T helper 1 cells. Immunity 40, 213–224. https://doi.org/10.1016/j.immuni.2013.12.013 (2014).
22. Arend, W., Palmer, G. & Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20–38 (2008).
23. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821–832 (2010).
24. Gorfu, G. et al. Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii. mBio https://doi.org/10.1128/mBio.01117-13 (2014).
25. Cai, G., Kastelein, R. & Hunter, C. A. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect. Immun. 68, 6932–6938 (2000).
26. Zamboni, D. S. & Lima-Junior, D. S. Inflammasomes in host response to protozoan parasites. Immunol. Rev. 265, 156–171. https://doi.org/10.1111/imr.12291 (2015).
27. Helbig, E. T., Opitez, B. & Sander, L. E. Adjuvant immunotherapies as a novel approach to bacterial infections. ImmunoTherapy 5, 365–381. https://doi.org/10.2217/imt.15.17 (2013).
28. Kupu, A. et al. ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo. J. Clin. Investig. https://doi.org/10.1172/JCI84978 (2016).
29. Kupu, A. et al. NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8+ T cells. Nat. Immunol. 13, 162–169 (2012).
30. Soudja, S. M. et al. Memory T-cell-derived interferon-gamma instructs potent innate cell activation for protective immunity. Immunity 40, 974–988. https://doi.org/10.1016/j.immuni.2014.05.005 (2014).
31. Boyman, O., Kovar, M., Rubinstein, M., Surh, C. & Sprent, J. Selective stimulation of T cell subsets with antibody–cytokine immune complexes. Science 311, 1924–1927 (2006).
32. Tenter, A. M., Heckeroth, A. R. & Weiss, L. M. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 30, 1217–1258. https://doi.org/10.1016/S0020-7519(00)00124-7 (2000).
33. Boyle, J. P., Saeij, J. P. & Boothroyd, J. C. Toxoplasma gondii: inconsistent dissemination patterns following oral infection in mice. Exp. Parasitol. 116, 302–305. https://doi.org/10.1016/j.exparpar.2007.01.010 (2007).
34. Malik, A. & Kanneganti, T. D. Inflammation activation and assembly at a glance. J. Cell Sci. 130, 3953–3963. https://doi.org/10.1242/jcs.207365 (2017).
35. Melo, M. B., Jensen, K. D. C. & Saeij, J. P. J. Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends in parasitology 27, 487–495. https://doi.org/10.1016/j.pt.2011.08.001 (2011).
36. Hakimi, M. A. & Bougdour, A. Toxoplasma’s ways of manipulating the host transcriptome via secreted effectors. Curr. Opin. Microbiol. 26, 24–31. https://doi.org/10.1016/j.mib.2015.04.003 (2015).
37. Hammoudi, P. M. et al. Fundamental roles of the golgi-associated toxoplasma aspartyl protease, ASPP, at the host–parasite interface. PLoS Pathog. 11, e1005211. https://doi.org/10.1371/journal.ppat.1005211 (2015).
38. Kupz, A., Zedler, U., Staber, M. & Kaufmann, S. H. A mouse model of latent tuberculosis infection to study intervention strategies to prevent reactivation. PLoS ONE 11, e0158849. https://doi.org/10.1371/journal.pone.0158849 (2016).
39. Kupz, A. et al. Contribution of Th1+ NK cells to protective IFN-γ production during Salmonella Typhimurium infections. Proc. Natl. Acad. Sci. 110, 2252–2257. https://doi.org/10.1073/pnas.1222047110 (2013).
40. Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 37, 772–786. https://doi.org/10.1016/j.immuni.2009.10.001 (2009).
41. Akbar, H., Dimier-Poisson, I. & Moire, N. Role of CD4+ Foxp3+ regulatory T cells in protection induced by a live attenuated, in vivo recombinant interleukin 2 administration enhances survival against a lethal dose of Toxoplasma gondii-infected mononcytic cells. Infect. Immun. 79, 756–766 (2011).
42. Vladimer, G. I. Evasion of human neutrophil-mediated host defense during Toxoplasma gondii. PLoS Pathog. 11, e1004731. https://doi.org/10.1371/journal.ppat.1004731 (2015).
43. Lima, T. S., Gov, L. & Lodoen, M. B. Evasion of human neutrophil-mediated host defense during Toxoplasma gondii infection in pregnant mice. J. Immunol. 199, 2855–2864. https://doi.org/10.4049/jimmunol.1700245 (2017).
44. Correa, G. et al. Inflammatory early events associated to the role of P2X7 receptor in acute murine toxoplasmosis. Immunobiology 222, 676–683. https://doi.org/10.1016/j.imbio.2016.12.007 (2017).
45. Miller, C. M. et al. Dysregulation of the inflammatory response to the parasite, Toxoplasma gondii, in P2X7 receptor-deficient mice. Int. J. Parasitol. 41, 301–308. https://doi.org/10.1016/j.ijpara.2010.10.001 (2011).
46. Moreira-Souza, A. C. A. et al. The P2X7 receptor mediates Toxoplasma gondii control in macrophages through canonical NLRP3 inflammasome activation and reactive oxygen species production. Front. Immunol. 8, 1257. https://doi.org/10.3389/fimmu.2017.01257 (2017).
47. Gov, L., Schneider, C. A., Lima, T. S., Pandori, W. & Lodoen, M. B. NLRP3 and potassium efflux drive rapid IL-1beta release from primary human monocytes during Toxoplasma gondii infection. J Immunol 199, 2855–2864. https://doi.org/10.4049/jimmunol.1700245 (2017).
48. Lima, T. S., Gov, L. & Lodoen, M. B. Evasion of human neutrophil-mediated host defense during Toxoplasma gondii infection. mBio https://doi.org/10.1128/mBio.02027-18 (2018).
49. Nadiparam, S. M. et al. In vivo biotinylation of the toxoplasma parasitophorous vacuole reveals novel dense granule proteins important for parasite growth and pathogenesis. mBio 7, e00808-00816. https://doi.org/10.1128/mBio.00808-16 (2016).
50. Gold, D. A. et al. The toxoplasma dense granule proteins GRA17 and GRA23 mediate the movement of small molecules between the host and the parasitophorous vacuole. Cell Host Microbe 17, 642–652. https://doi.org/10.1016/j.chom.2015.04.003 (2015).
51. Franco, M. et al. A novel secreted protein, MYR1, is central to toxoplasma’s manipulation of host cells. mBio 7, e02231-e122315. https://doi.org/10.1128/mBio.02231-15 (2016).
52. Marino, N. D. et al. Identification of a novel protein complex essential for effector translocation across the parasitophorous vacuole membrane of Toxoplasma gondii. PLoS Pathog 14, e1006828. https://doi.org/10.1371/journal.ppat.1006828 (2018).
53. Naor, A. et al. MYR1-dependent effectors are the major drivers of a host cell’s early response to toxoplasma, including counteracting MYR1-independent effects. mBio 9, e20401-02417. https://doi.org/10.1128/mBio.02401-17 (2018).
54. Carson, W. E. et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395–1403 (1994).
55. Zhu, Z. & Domaica, C. Cytochrome regulation of natural killer cell effector functions. BioFactors 36, 274–288 (2010).
56. Li, C. C., Murakami, M., Sakamoto, A., Kappler, J. & Marrack, P. Control of homeostasis of CD8+ T memory cells by opposing cytokines. Science 288, 675–678 (2000).
57. Sprent, J. & Surch, C. D. Generation and maintenance of memory T cells. Curr. Opin. Immunol. 13, 248–254 (2001).
58. Li, X. C. et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. J. Immunol. 156, 663–669 (1996).
59. Lieberman, L. A., Villegas, E. N. & Hunter, C. A. Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii. Infect. Immun. 72, 6729–6732. https://doi.org/10.1128/iai.72.11.6729-6732.2004 (2004).
60. Khan, I. A. et al. Treatment with soluble interleukin-15Ralpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response. J. Exp. Med. 195, 1463–1470 (2002).
61. Villagas, E. N., Lieberman, L. A., Carding, S. R. & Hunter, C. A. Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon. Infect. Immun. 70, 4757–4761 (2002).
62. Sharma, S. D., Hofflin, J. M. & Remington, J. S. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J. Immunol. 135, 4160–4163 (1985).
63. Shirahata, T., Muroya, N., Ohta, C., Goto, H. & Nakane, A. Enhancement by recombinant human interleukin 2 of host resistance to Toxoplasma gondii infection in pregnant mice. Microbiol. Immunol. 37, 583–590 (1993).
64. Stoklasek, T. A., Schluns, K. S. & Lefrançois, L. Combined IL-15/IL-15Ra immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177, 6072–6080 (2006).
65. Stonier, S. & Schluns, K. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 127, 85–92 (2010).
72. Votarova, P., Tomala, J. & Kovar, M. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Ra-Fc chimera. *Immunol. Lett.* 159, 1–10. https://doi.org/10.1016/j.imlet.2014.01.017 (2014).
73. Shevach, E. M. Application of IL-2 therapy to target T regulatory cell function. *Trends Immunol.* 33, 626–632. https://doi.org/10.1016/j.ti.2012.07.007 (2012).
74. Liu, Y. et al. Adoptive transfer of Treg cells counters adverse effects of *Toxoplasma gondii* infection on pregnancy. *J. Infect. Dis.* 210, 1435–1443. https://doi.org/10.1093/infdis/jiu265 (2014).
75. Tenorio, E. P., Fernandez, J., Castellanos, C., Olguin, J. E. & Saavedra, R. CD4+ Foxp3+ regulatory T cells mediate *Toxoplasma gondii*-induced T-cell suppression through an IL-2-related mechanism but independently of IL-10. *Eur. J. Immunol.* 41, 3529–3541. https://doi.org/10.1002/eji.201141507 (2011).
76. Olguin, J. E. et al. Adoptive transfer of CD4+(+)Foxp3(+) regulatory T cells to C57BL/6J mice during acute infection with *Toxoplasma gondii* down modulates the exacerbated Th1 immune response. *Microbes Infect.* 17, 586–595. https://doi.org/10.1016/j.micinf.2015.04.002 (2015).
77. Salinas, N., Olguin, J. E., Castellanos, C. & Saavedra, R. T cell suppression in vitro during *Toxoplasma gondii* infection is the result of IL-2 competition between Tregs and T cells leading to death of proliferating T cells. *Scand. J. Immunol.* 79, 1–11. https://doi.org/10.1111/sji.12120 (2014).
78. Bur rak, K. S. et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural killer cells. *Immunity* 48, 760–772.e764. https://doi.org/10.1016/j.immuni.2018.03.012 (2018).
79. Epardaud, M. et al. Interleukin-15/interleukin-15Ra complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. *Can. Res.* 68, 2972–2983. https://doi.org/10.1158/0008-5472.can-08-0045 (2008).
80. Dubois, S., Patel, H. H., Zhang, M., Waldmann, T. A. & Müller, J. R. Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD69+/CD44 high T cells and its antitumor action. *J. Immunol.* 180, 2099–2106 (2008).
81. Huntington, N. D. et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. *J. Exp. Med.* 206, 25–34. https://doi.org/10.1084/jem.20082013 (2009).
82. Hamilton, S. E., Schenkel, J. M., Akue, A. D. & Jameson, S. C. IL-2 Complex treatment can protect naive mice from bacterial and viral infection. *J. Immunol.* 185, 6584–6590. https://doi.org/10.4049/jimmunol.1001215 (2010).
83. Boyman, O., Kološ, A. G. & Raebel, M. E. Modulation of T cell responses by IL-2 and IL-2 complexes. *Clin. Exp. Rheumatol.* 33, S54–57 (2015).
84. Molloy, M. J., Zhang, W. & Usherwood, E. J. Cutting edge: IL-2 Immune complexes as a therapy for persistent virus infection. *J. Immunol.* 182, 4512–4515. https://doi.org/10.4049/jimmunol.0804175 (2009).
85. Kamimura, D. et al. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. *J. Immunol.* 177, 306–314. https://doi.org/10.4049/jimmunol.177.1.306 (2006).
86. Tomala, J., Chmelova, H., Mrkván, T., Rihova, B. & Kovar, M. In Vivo Expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and Anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. *J. Immunol.* 183, 4904–4912. https://doi.org/10.4049/jimmunol.0900284 (2009).
87. Caudana, P. et al. IL-2/anti-IL-2 complex combined with CTLA4-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation. *Cancer Immunol. Res.* https://doi.org/10.1158/2326-6066.cir-18-0697 (2019).
88. Masters, S. L. et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. *Immunity* 37, 1009–1023. https://doi.org/10.1016/j.immuni.2012.08.027 (2012).
89. Shen, B., Brown, K. M., Lee, T. D. & Sibley, L. D. Efficient gene disruption in diverse strains of *Toxoplasma gondii* using CRISPR/CAS9. *mbio* 5, e01114-01114. https://doi.org/10.1128/mBio.01114-14 (2014).
90. Striepen, B., He, C. Y., Matrajt, M., Soldati, D. & Roos, D. S. Expression, selection, and organellar targeting of the green fluorescent protein in *Toxoplasma gondii*. *Mol. Biochem. Parasitol.* 92, 325–338 (1998).
91. Weigmann, B. et al. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. *Nat. Protoc.* 2, 2307–2311. https://doi.org/10.1038/nprot.2007.315 (2007).
92. Melgar, S., Karlsson, A. & Michaelsson, E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. *Am. J. Physiol. Gastrointest. Liver Physiol.* 328, G1328–G1338. https://doi.org/10.1152/ajpgi.00467.2004 (2005).
93. Buffet, P. A., Sulahian, A., Garin, Y. J., Nassar, N. & Derouin, F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. *Antimicrob. Agents Chemother.* 39, 2167–2168 (1995).
94. Sester, D. P. et al. Assessment of inflammasome formation by flow cytometry. *Carr. Protoc. Immunol.* 114, 14401–144029. https://doi.org/10.1002/cpim.13 (2016).

**Acknowledgments**

This work was supported by the National Health and Medical Research Council of Australia (NHMRC) through a CJ Martin Biomedical Early Career Fellowship (APP1052764) and a Career Development Level I Fellowship (APP1140709) to A.K. A.K and C.M.M. also acknowledge support through a Capacity Building Grant (15031) provided by the Australian Institute of Tropical Health and Medicine (AIITHM) via the Queensland Government. We thank Michael E. Grigg (NIH, USA) for generously providing the *T. gondii* ME49-RFP, and Seth Masters (WEHI, Melbourne, Australia) for providing *Nlrp1<sup>−/−</sup>* and *Nlrp3<sup>−/−</sup>* mice. We are grateful to Dominique Soldati-Favre (University of Geneva) for her insights into GRA proteins.

**Author contributions**

A.K., C.M.M. and N.C.S. conceived the study; A.K., C.M.M., R.A.W., J.A.W., P.R.G. and S.P. performed experiments; P.M.H. and P.R.G. provided reagents and intellectual input. A.K. performed data analysis and wrote the manuscript. N.C.S and C.M.M. commented extensively on, and revised the manuscript; all coauthors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** is available for this paper at https://doi.org/10.1038/s41598-020-70102-1.

**Correspondence** and requests for materials should be addressed to A.K.

**Reprints and permissions information** is available at www.nature.com/reprints.
